Search
Biodesix Inc
BDSXAdd to Watchlist
21.990USD
-2.510-10.24%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
174.92MMarket Cap
LossP/E TTM
More Details of Biodesix Inc Company
Biodesix, Inc. is a diagnostic solutions company. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
Biodesix Inc Info
Ticker SymbolBDSX
Company nameBiodesix Inc
IPO dateOct 28, 2020
CEOHutton (Scott)
Number of employees273
Security typeOrdinary Share
Fiscal year-endOct 28
Address919 West Dillon Road
CityLOUISVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code80027
Phone13034170500
Websitehttps://www.biodesix.com/
Ticker SymbolBDSX
IPO dateOct 28, 2020
CEOHutton (Scott)
Company Executives of Biodesix Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John Patience
Mr. John Patience
Independent Chairman of the Board
Independent Chairman of the Board
375.81K
+0.36%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
152.98K
-0.00%
Mr. Hany Massarany
Mr. Hany Massarany
Independent Director
Independent Director
18.17K
-0.01%
Dr. Jon Faiz Kayyem, Ph.D.
Dr. Jon Faiz Kayyem, Ph.D.
Independent Director
Independent Director
17.88K
-0.01%
Ms. Robin Harper Cowie
Ms. Robin Harper Cowie
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
17.14K
+8.24%
Mr. Kieran O'Kane
Mr. Kieran O'Kane
Chief Commercial Officer
Chief Commercial Officer
10.12K
+6.05%
Ms. Jean M. Franchi, CPA
Ms. Jean M. Franchi, CPA
Independent Director
Independent Director
5.41K
-0.02%
Mr. Scott Hutton
Mr. Scott Hutton
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Lawrence T. (Lair) Kennedy, Jr.
Mr. Lawrence T. (Lair) Kennedy, Jr.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John Patience
Mr. John Patience
Independent Chairman of the Board
Independent Chairman of the Board
375.81K
+0.36%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
152.98K
-0.00%
Mr. Hany Massarany
Mr. Hany Massarany
Independent Director
Independent Director
18.17K
-0.01%
Dr. Jon Faiz Kayyem, Ph.D.
Dr. Jon Faiz Kayyem, Ph.D.
Independent Director
Independent Director
17.88K
-0.01%
Ms. Robin Harper Cowie
Ms. Robin Harper Cowie
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
17.14K
+8.24%
Mr. Kieran O'Kane
Mr. Kieran O'Kane
Chief Commercial Officer
Chief Commercial Officer
10.12K
+6.05%
FAQs
Who are the top five shareholders of Biodesix Inc?
The top five shareholders of Biodesix Inc are: Mr. John Patience
How many institutions hold shares of Biodesix Inc (BDSX)?
As of 2026Q1, 111 institutions hold shares of Biodesix Inc, with a combined market value of approximately 3.03M, accounting for 29.99% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 290072.00.
What is the biggest source of revenue for Biodesix Inc?
In 2026Q1, the Lung Diagnostic Testing business generated the highest revenue for Biodesix Inc, amounting to 79.20M and accounting for 89.49% of total revenue.